From Hofmann to the Haight Ashbury, and into the future: the past and potential of lysergic acid diethlyamide.
Since the discovery of its psychedelic properties in 1943, lysergic acid diethylamide (LSD) has been explored by psychiatric/therapeutic researchers, military/intelligence agencies, and a significant portion of the general population. Promising early research was halted by LSD's placement as a Schedule I drug in the early 1970s. The U.S. Army and CIA dropped their research after finding it unreliable for their purposes. NSDUH estimates that more than 22 million (9.1% of the population) have used LSD at least once in their lives. Recently, researchers have been investigating the therapeutic use of LSD and other psychedelics for end-of-life anxiety, post-traumatic stress disorder (PTSD), cancer, and addiction treatment. Adverse psychedelic reactions can be managed using talkdown techniques developed and in use since the 1960s.
David E
DE
Smith
Glenn E
GE
Raswyck
Leigh Dickerson
LD
Davidson
D000818:Animals; D035843:Biomedical Research / Q000266:history / Q000639:trends; D064420:Drug-Related Side Effects and Adverse Reactions / Q000523:psychology / Q000628:therapy; D005544:Forecasting; D006213:Hallucinogens / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D011583:Psychological Warfare; D012495:San Francisco; D019966:Substance-Related Disorders
D006213:Hallucinogens; D008238:Lysergic Acid Diethylamide